Published online Jul 15, 2025. doi: 10.4239/wjd.v16.i7.107673
Revised: April 20, 2025
Accepted: June 3, 2025
Published online: July 15, 2025
Processing time: 109 Days and 23.7 Hours
The rising global incidence of diabetes mellitus (DM) and hyperuricemia presents a growing challenge to public health systems worldwide. Urate transporter-1 (URAT1), a key renal urate transporter, has emerged as a promising therapeutic target for managing DM and its associated complications. Growing evidence suggests that URAT1’s role in metabolic disorders extends beyond its function in the kidney. Specifically, URAT1 can influence uric acid metabolism in multiple tissues including neural, hepatic, vascular smooth muscle, cardiac, and adipose tissue, thereby contributing to insulin resistance, inflammation, and end-organ damage. In this review, we comprehensively examine the extra-renal functions of URAT1, focusing on its roles in the hematopoietic system, heart, liver, adipose tissue, and vascular endothelium in the context of DM. This analysis highlights the multi-organ mechanisms through which URAT1 exerts its effects, offering valuable insights into its potential as a therapeutic target for this complex sys
Core Tip: Emerging evidence highlights the extra-renal roles of urate transporter-1 (URAT1) in diabetes mellitus, extending beyond its canonical function in renal urate reabsorption. URAT1-mediated uric acid uptake in tissues such as adipose, liver, heart, endothelium, and hematopoietic cells exacerbates insulin resistance, oxidative stress, and inflammation, driving diabetic complications. Pharmacological inhibition of URAT1 with agents like dotinurad, benzbromarone, or probenecid attenuates these pathological processes by reducing uric acid influx, restoring insulin signaling, and suppressing pro-inflammatory pathways. This review underscores URAT1 as a pivotal therapeutic target for mitigating multi-organ dysfunction in diabetes mellitus, offering novel strategies to address systemic metabolic and inflammatory derangements.